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ABSTRACT 
 
CD147 AS A POTENTIAL THERAPEUTIC TARGET IN GLIOBLASTOMA 
TREATMENT 
By  
Beau Adams 
 
Glioblastoma (GBM) tumors are the most common and lethal form of cancer in 
the central nervous system (CNS). GBM tumors appear to contain a mixture of different 
cell types, which makes them difficult to treat. GBM cells exhibit altered morphology 
from normal cells on several different levels, which highlights different pathways to 
potentially target for therapeutic treatments. The human surface glycoprotein CD147, 
also known as basigin, is expressed at significantly higher levels in GBMs compared to 
non-neoplastic brain tissue. Furthermore, levels of CD147 expression correlate with brain 
tumor progression and show the highest expression in GBM. Here, we suppressed tumor 
cell growth using anti-CD147 monoclonal antibodies. An apoptosis/necrosis assay 
suggests that GBM cells treated with anti-CD147 monoclonal antibodies were not 
experiencing a form of induced cell death. Rather, our cell proliferation assay results 
suggest that anti-CD147 monoclonal antibody treated cells had significantly deceased cell 
proliferation when compared with control cells. Together, these results show that CD147 
is a potential therapeutic target for GBM treatment.  
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 1 
INTRODUCTION 
 
 
 
 
Glioblastoma (GBM) is the most common and lethal form of primary cancer in 
the central nervous system (CNS). Glioblastoma is a type of tumor that develops from 
glial cells, called astrocytes, which function to support nerve cells1. Glioblastomas are 
highly malignant due to their fast growth rates and the extensive blood vessel networks 
that form near them2. During development of the tumor, GBMs appear to contain a 
mixture of specific differentiated cell types such as oligodendrocytes and ependymal 
cells. As a result, some GBM cells may respond to specific therapies while others may 
not respond at all, making GBMs extremely difficult to treat. Despite advances in cancer 
therapy such as immunotherapy, the prognosis for GBM patients remains poor. Standard 
GBM treatments include partial removal, chemotherapy, and radiation3. Chemotherapy 
involves the use of drugs intended to kill cancer cells by stopping growth and 
reproduction. Radiation involves the use of high-energy waves to damage tumor cell 
DNA, which halts cell division and eventually destroys them. Unfortunately, these 
treatments are only beneficial for a short period of time and can have negative effects 
upon the surrounding normal tissues. The survival rate for GBM patients one-year post 
diagnosis is 33% while the survival rate after five years is 4.5%4. Many research 
laboratories across the world are working to find a potential therapeutic target for GBM 
to increase the survival rates and improve the treatments of this deadly disease.  
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The growth and spread of a tumor (called metastasis) involves several steps, 
including increased cell proliferation, changes in cell motility leading to invasion of 
surrounding tissues, and the formation of new blood vessels (angiogenesis). The process 
of angiogenesis ensures that metabolically active tissues, including cancer, are never 
more than a few hundred micrometers away from capillaries5. Angiogenesis is stimulated 
when vascular endothelial growth factor (VEGF) binds to tyrosine kinase receptors 
(VEGF-Rs), which then leads to activation of several downstream pathways that regulate 
angiogenesis. Capillaries are crucial for the process of nutrient/metabolite exchange and 
provide tissues with a consistent oxygen supply to metabolize substrates that are needed 
for energy6. This is important because cancer cells require this nutrient/metabolite 
exchange in order to survive7. Anti-angiogenic therapies designed to prevent the growth 
of new blood capillaries are used to combat several diseases, including cancer. These 
‘angiogenesis inhibitors’ generally block the activation of VEGF receptors. The drugs 
bind to either VEGF and/or VEGF-Rs, blocking receptor binding and subsequent 
activation of downstream signaling8. Angiogenic inhibitors have shown promise in GBM 
patients but unfortunately exhibit a high percentage of relapse, which calls for a larger 
understanding of the mechanisms involved in tumor growth. 
Rapidly proliferating cells can become resistant to the body’s normal defenses, 
and some can evade endogenous cell death programs designed to prevent unwanted cell 
growth9. Normally, cytotoxic and helper T cells inhibit cancer development through 
production of cytokines and cytotoxins9. However, things such as chronic inflammation 
can override these effects to promote cancer. When acute immune responses fail to 
eliminate cancer cells, unresolved chronic inflammation promotes tumor cell growth and 
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angiogenesis9. The human immune system is normally capable of eliminating cancer cells 
that express mutated proteins (neoantigens), which are molecules encoded by tumor-
specific mutated genes. However, increases in cancer cell proliferation also generates 
cells that can evade immune responses, allowing some cancer cells to escape immune 
system elimination9. Increased cell proliferation leads to the production of immune 
suppressive cytokines, either by tumor cells or normal cells present in the tumor 
microenvironment. These cytokines, such as TNF-alpha, IL-1, and IL-6 assist in the 
evasion of immune surveillance by weakening T cell response9. For example, TNF-α 
promotes cell survival via TNFR1 through its activation of specific transcription factors, 
which cause downstream activation of the PI3K/Akt/MDM2 pathway (expanded upon in 
the following pages)10. IL-1 induces expression of metastatic genes involved in tumor 
progression such as VEGF, TNF-α, and other interleukins11. IL-6 protects tumor cells 
from oxidative stress, DNA damage, and apoptosis by facilitating signaling pathways 
involved in cell survival, which also includes the PI3K/Akt/MDM2 pathway12.  
Another dangerous property of GBMs is their ability to invade nearby tissues, 
leading to another obstacle of treatment. A good way to summarize this process is the 
invasion-metastasis cascade13. This cascade occurs when primary tumor cells invade the 
surrounding extracellular matrix (ECM) followed by invasion of the lumina of blood 
vessels, where tumor cells can be transported through the vasculature. Finally, the tumor 
cells can move into the parenchyma of distant tissues and then reinitiate their 
proliferation. These invasive properties contribute to tumor survival and induce 
molecular changes that maximize metastasis13. An understanding of this process is 
critical for the development of new techniques to diagnose and treat GBM. The first step 
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in the metastatic process is local invasion, which refers to cancer cells from the primary 
tumor entering adjacent tissue. In order to invade the tissue, cancer cells must penetrate 
the basement membrane (BM), a special type of extracellular matrix that separates 
epithelial and stromal components10. From here, these cancer cells must invade lymphatic 
and blood vessels (intravasation). Intravasation occurs when molecular changes allow 
these cancer cells to cross endothelial cell barriers that make up blood vessel walls. 
Examples of molecules promoting intravasation include transforming growth factor-β 
(TGFβ), epidermal growth factor (EGF), and colony stimulating factor-1 (CSF-1)14. Once 
cancer cells have intravasated into blood vessels, they become circulating tumor cells 
(CTCs) and must survive to successfully metastasize. In the absence of any anchorage, 
normal cells in circulation would usually go through anoikis – a type of apoptosis due to 
loss of anchorage. Cancer cells are able to overcome anoikis due to specific molecules 
such as tyrosine kinase receptor B (TrkB) that assists in suppression of the immune 
response15. In a study by Douma et al., it was shown that TrkB activates the 
phosphatidylinositol-3-OH kinase/protein kinase B pathway which induced formation of 
cellular aggregates that survived in suspension – therefore overcoming anoikis15. 
Eventually, the CTCs arrest at specific sites and begin to invade the walls of surrounding 
vessels, making direct contact with tissue parenchyma. This process is known as 
extravasation13. In a recent study by Gao et al., CTCs were identified in 77% of 
glioblastoma patients16. CTCs are thought to be one of the main reasons for tumor 
recurrence in many forms of cancer, including GBM17. 
An example of a molecule that may be involved in all of these tumor-promoting 
properties is the human surface glycoprotein basigin. The basigin gene is located at p13.3 
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on chromosome 19 and consists of ten exons spanning 12 kb18. Basigin is a member of 
the immunoglobulin family of cell surface proteins and is expressed as four different 
isoforms. The transmembrane domain is almost completely conserved across all species, 
while the cytoplasmic domain is only moderately conserved19. The largest isoform, 
known as basigin-1, has three immunoglobulin domains within the extracellular domain 
and is expressed specifically in the retina18. Basigin-2, also commonly called CD147, is 
the isoform expressed at relatively high levels in many cell types and possesses two 
immunoglobulin domains within the extracellular domain. The core protein portion of 
basigin-2 is 28 kDa18, and during processing in the cell, it becomes heavily glycosylated 
on three asparagine residues resulting in an increase in its weight to 43-66 kDa20. For the 
purpose of this thesis, basigin-2 will be referred to as CD147 unless specified otherwise. 
A study by Jia et al. looked closer at CD147 glycosylation, specifically its interaction 
with other molecules. Since CD147 associates with caveolin-1 (Cav-1), the authors 
looked into its effect on glycosylation. Using an RNA interference (RNAi) model, it was 
shown that downregulation of Cav-1 suppressed the conversion of CD147 into its higher 
glycosylated form, exhibiting the importance of the CD147/Cav-1 association21. 
Additionally, it was originally thought that CD147 was only able to exhibit stimulatory 
activity if glycosylated. However, a study by Belton et al. demonstrated that activation is 
not dependent upon glycosylation of the CD147 ligand22.  
CD147 is normally involved in a number of biological processes including 
embryonic development, sensory regulation, and immunological responses18. While 
CD147 expression is elevated in rapidly proliferating tumor cells, it is also found in 
leukocytes, macrophages, epithelial cells (blood vessel walls), red blood cells, and the 
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endometrium; but not in normal glia23-24. A study by Geng et al. found that CD147 
promoted M1 macrophage activity in the lungs, which induced the differentiation of cells 
in lung fibrosis25. Another study by Coste et al. examined the function of CD147 in red 
blood cells. In this study, anti-CD147 monoclonal antibody (mAb) treatment disrupted 
the circulation of red blood cells, leading to cellular trapping in the spleen24. In a study of 
CD147 deficient mice, the majority of embryos died during implantation. The surviving 
mutant mice were born underdeveloped and died well before adulthood26. In normal 
mice, CD147 was highly expressed in the embryo proper, endometrium, and trophoblast 
cells. The early deaths of knockout-CD147 mice suggest its important role in 
embryogenesis and reproduction22. CD147 has also been found to play an important role 
in the sensory nervous system, as the survival and function of photoreceptors in the retina 
is dependent upon CD147 through its affiliation with monocarboxylate transporters 
(MCTs) in the plasma membrane of retinal cells27. In the immune system, recent studies 
have shown that CD147 affects T-cell activation as well as T-cell development28. In 
CD147-knockout mice, thymus development was arrested in early stages28. Furthermore, 
T cell proliferation was significantly increased when CD147 was knocked down using 
siRNA-mediated gene silencing29. Through confocal microscopy, it was found that 
CD147 is recruited to the immunological synapse during T cell activation30. The 
immunological synapse is the space between the antigen-presenting cell and a 
lymphocyte. Using a CD147-EGFP (enhanced green fluorescent protein), Ruiz et al. 
observed that CD147 translocated from the plasma membrane to the immunological 
synapse upon T cell activation31.  
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In cancer cells, CD147 expression levels are significantly higher than in normal 
tissue. Furthermore, the levels of CD147 expression correlate directly with tumor severity 
and progression in gliomas and show the highest expression in GBM32.  In fact, CD147 
expression is upregulated in nearly every type of cancer, including breast, cervical, colon, 
lung, and melanoma among others33.  In GBM, CD147 promotes tumor growth, inhibits 
cell death, and enhances the invasiveness of tumor cells34. Interactions with many 
specific proteins are a key part of CD147 function. CD147 acts as an extracellular matrix 
metalloproteinase (MMP) inducer by stimulating the release of MMPs from fibroblast 
cells. MMP induction is initiated when a soluble basigin ligand binds to a CD147 cell 
surface receptor, stimulating the ERK 1/2 signaling pathway which induces expression of 
MMPs22. Matrix metalloproteinases can then degrade the extracellular matrix and 
therefore assist with tumor invasiveness, angiogenesis, and increased cell survival. 
CD147 also contributes to angiogenesis independently of MMPs by increasing vascular 
endothelial growth factor (VEGF), which assists in blood vessel formation as discussed 
earlier35. In a study by Tang et al., VEGF expression was induced in a CD147 dose 
dependent manner. Furthermore, VEGF expression was inhibited by suppressing CD147 
expression in tumor cells by using an anti-CD147 mAb31. CD147 has been shown to act 
as a coreceptor for VEGFR2 in both tumor and endothelial cells. Since CD147 is 
overexpressed in most cancers, this causes enhanced activation of the VEGFR2 which 
leads to increased angiogenesis for tumor cells36.  
CD147 also interacts with cell surface transmembrane glycoproteins called 
integrins, and the association of CD147 with integrins is important for cell adhesion, 
migration, metastasis, and cell signaling37. In CD147 mutant mice, the disruption of this 
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interaction lead to cellular dysfunction such as abnormal distribution of organelles, 
including the mitochondria, nuclei, and endoplasmic reticulum37-38. In multiple sclerosis, 
CD147 regulates alpha-4 integrin expression on T cells. A flow cytometry assay showed 
that T cells treated with an anti-CD147 mAb had reduced alpha-4 integrin expression on 
the cell surface39. While examining the mechanism by which this occurs, Agrawal et al. 
showed that anti-CD147 mAb treatment inhibited the nuclear factor kB (NFkB) pathway. 
To test this, the authors examined IκBα protein levels 2 hours post anti-CD147 mAb 
treatment39. IκBα is a protein that functions to inhibit NFkB by interfering with its cell 
signaling. Western blot analysis demonstrated that when treated with the anti-CD147 
mAb, IκBα levels decreased in the cells39.  
Another important protein group that CD147 associates with are cyclophilins, 
which bind extracellularly and transmit their signals. Cyclophilin A is a peptidylprolyl 
isomerase normally expressed inside cells but is secreted in response to immunological 
stimuli such as inflammation and antigen presentation. Secreted cyclophilins promote 
chemotactic activity for neutrophils, eosinophils, and T cells18. Chemotaxis occurs when 
a cell moves in response to a chemical stimulus. CD147 has been shown to act as a 
receptor for cyclophilin A and mediate its chemotactic activity towards target cells. This 
CD147-cyclophilin interaction is important for the inflammatory process of several 
diseases, including GBM40. A recent study by Jin et al. demonstrated that cyclophilin A is 
secreted by cells in response to oxidative stress41. Therapeutic agents that have reduced 
CD147 expression exhibited a significant anti-inflammatory response, suggesting that the 
CD147/cyclophilin interaction could be a potential target for anti-inflammatory therapy. 
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CD147 inhibition through an anti-CD147 mAb reduced inflammation by more than 50% 
in mouse models with lung inflammation, asthma, and rheumatoid arthritis40.  
CD147 is also indirectly involved in the transport of metabolites such as lactate 
and pyruvate across the plasma membrane. Monocarboxylate transporters (MCTs) play a 
central role in this transport, and CD147 forms a complex on the cell surface with these 
transporters42. Walters et al. used immunofluorescence analysis to demonstrate that 
CD147 specifically interacts with both MCT1 and MCT4 in cancer cells43. MCTs are 
involved in the regulation of glycolytic metabolism, which is crucial for the expansion of 
neoplastic tissue44. Under low oxygen (hypoxic) conditions, glucose is catabolized to 
lactate through glycolysis to form ATP because the mitochondria can’t use oxidative 
phosphorylation to create ATP without oxygen. Cancer cells can also produce lactate 
under aerobic conditions – switching from glycolysis and oxidative phosphorylation to 
strictly cytosolic glycolysis45. This phenomenon is called the ‘Warburg effect’ thanks to 
its leading contributor, Otto Warburg (figure 1). Lactate, the end product of anaerobic 
glycolysis, causes acidosis in cells and must be pumped out for cancer cells to remain 
functional42. In a study by Baba et al., blocking expression of the CD147/MCT complex 
using an anti-CD147 mAb was shown to decrease the number of melanoma and colon 
cancer cells in vitro through an accumulation of lactate and a decreased pH. 
Immunofluorescence analysis showed that after mAb treatment, MCT was being 
internalized into the cell, suggesting internalization of the CD147/MCT complex. This is 
problematic because the CD147/MCT complex carries out its function on the cell surface. 
This response was specific for cancer cells, and not for normal fibroblasts42. In the study, 
it is important to note the authors did not detect apoptosis in the anti-CD147 mAb treated 
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cells, and assumed the decreased cell numbers were caused by necrosis. This is a major 
assumption because other factors could be causing this, such as an interruption of the cell 
cycle leading to decreased proliferation. 
Eukaryotic cells have two main mechanisms of cell death – apoptosis and 
necrosis. Apoptosis is a process of enzyme-mediated, programmed cell death whereas 
necrosis is described as accidental cell death due to environmental stress. The 
morphology of cells undergoing apoptosis is characterized by cytoplasmic condensation 
and cellular fragmentation into membrane-bound fragments46. Specific proteases called 
caspases are integral to the apoptotic response. Caspase activation is involved in the 
production of pro-inflammatory cytokines such as IL-147. Caspase proteolysis of 
substrates is responsible for the morphological changes in apoptotic cells. Another 
caspase-dependent process used for apoptosis detection is phosphatidylserine (PS) 
exposure. In a paper by Martin et al., it was shown that inhibition of specific caspases 
lead to inhibition of PS externalization.48. Molecules called flippases are responsible for 
keeping PS in the inner leaflet of the plasma membrane, while scramblases are 
responsible for translocating PS to the outer leaflet49. When cells begin apoptosis, PS 
moves from the inner leaflet to the outer leaflet of the plasma membrane, which exposes 
it to be detected46. The morphology of cells that experience necrotic cell death is 
significantly different from apoptosis. Necrotic cell death is accompanied by cell 
swelling, organelle distension, degradation of nuclear DNA, and plasma membrane 
autophagy31. Necrosis is considered to be passive because it requires minimal energy and 
isn’t regulated by any homeostatic mechanism. Necrosis occurs due to several 
 11 
environmental factors such as nutrient deprivation, reactive oxygen species, toxin 
exposure, and severe changes in physiological conditions50.  
Aside from cell death, inhibition of signaling pathways can also lead to a 
decreased number of cells, this time without actually killing them. In a 2014 paper by 
Huang et al., it was shown that CD147 significantly suppresses p53 protein levels51. P53 
is a tumor suppressor gene that regulates cellular metabolic stress responses. P53 activity 
is very low in normal cells, but is increased in response to cellular stress such as DNA 
damage and oncogene activation52. The primary regulator of p53 is mouse double minute 
2 homolog (MDM2), which functions to inhibit p53 transcriptional activation. MDM2 
does this by acting as a ubiquitin ligase, which induces proteasome degradation to 
decrease p53 protein levels52. Many studies have shown that p53 inhibits the expression 
of glucose transporters GLUT1 and GLUT4, which are both crucial for energy 
production51. P53 is downstream of the PI3K/Akt/MDM2 signal transduction pathway, 
which is critical in cellular functions such as proliferation, glucose metabolism, and 
angiogenesis (figure 2). Specific growth factors lead to activation of this pathway and one 
of these key regulators is epidermal growth factor (EGF) and its receptor EGFR. EGFR 
lays directly upstream of the PI3K/Akt/MDM2 pathway and its activation leads to 
activation of the pathway53. EGFR is a receptor tyrosine kinase (RTK) that is upregulated 
in several types of cancers including breast cancer, pancreatic cancer, and GBM53. To 
become activated, RTKs generally require ligand binding that eventually leads to 
phosphorylation of the receptor. Interestingly enough, in cancer, RTKs can become 
phosphorylated in the absence of a ligand. Overexpression or mutations of RTKs can lead 
to clustering of receptors, causing them to homodimerize and become phosphorylated 
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without a ligand54. Interestingly enough, EGFR variant 3 (EGFRvIII), which is a ligand-
independent receptor, is overexpressed in GBM55. EGFR is known for its role in cell 
proliferation and inhibition of apoptosis, which is why it is labeled as a proto-oncogene. 
A proto-oncogene is a normal gene that has potential to become mutated and eventually 
cause cancer. In a paper by Grass et al, it was demonstrated that CD147 forms a complex 
with EGFR in lipid-raft membrane domains56. To test this, a proximity ligation assay 
(PLA) that examines the association of specific proteins was conducted. The assay 
demonstrated that there is close association between CD147 and EGFR inside membrane 
fractions of cancer cells56. Given that CD147 is also directly upstream of the 
PI3K/Akt/MDM2 signaling pathway, it was hypothesized by Huang et al. that CD147-
activated Akt may lead to the degradation of p53. Upon further analysis, it was found that 
phosphorylation of Akt and MDM2 was significantly decreased when CD147 was either 
knocked down or knocked out, all while p53 levels increased. These results suggest that 
CD147 may activate the PI3K/Akt/MDM2 pathway to inhibit p53 by promoting its 
degradation51. Furthermore, the study demonstrated an inverse correlation between lactic 
acidosis and PI3K/Akt activity. Huang et al. found that Akt activity was reduced by a 
MCT1 specific siRNA or a MCT1 inhibitor, while it was significantly increased in MCT1 
overexpressing cells51. Taken together, this data suggests that the CD147/MCT complex 
along with EGFR activity play a role in activating the PI3K/Akt/MDM2 pathway. To 
conclude, inhibiting CD147 may subsequently inhibit the PI3K/Akt/MDM2 pathway, 
leading to increased p53 expression and its tumor suppressing properties.  
In the human body, cells are either surrounded by the extracellular matrix or are 
in direct contact with other cells. However, most in vitro biology techniques culture cells 
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in a two-dimensional (2D) monolayer on plastic, which isn’t representative of a cells 
natural microenvironment57. In an attempt to mimic the body as accurately as possible, 
three-dimensional (3D) cell culturing techniques have recently been developed. In the 
thesis presented here, an improved cell culturing technique was developed to culture 
multi-cellular 3D spheroids using ultra-low attachment 96-well plates. Three-dimensional 
growth of cells is now regarded as a more reliable model in comparison to single 
adherent cells when conducting cell culture assays. Spheroids possess several similar 
features of tumors such as cell interactions, response, and resistance58. Improvements of 
several other physiological aspects have also been highlighted using 3D cell culture, such 
as – cell viability, morphology, proliferation, differentiation, invasion, angiogenesis, and 
cell function59. The 3D spheroid model more closely imitates in vivo cells, with the 
expectation that it will give the most accurate and reliable results. In the work discussed 
below, we used a 3D cell culture system and anti-CD147 mAbs to test whether CD147 
could be targeted for anti-tumor therapy.  
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AIMS AND GOALS 
 
 
 
 Glioblastoma (GBM) is the most common and lethal form of primary cancer in 
the central nervous system. While normal glial cells do not express CD147, the 
transmembrane glycoprotein is highly overexpressed in GBM. CD147 contributes to 
critical tumor promoting properties, which eventually lead to increased tumor cell 
survival. This presents an important target for a potential therapeutic treatment. CD147 
forms a complex with monocarboxylate transporters (MCTs) on the cell surface, which 
serves as an important regulator of intracellular homeostasis. Activation of this complex 
may lead to activation of the PI3K/Akt/MDM2 pathway, which subsequently inhibits 
p53, an important tumor suppressing protein. A 2008 paper by Baba et al. showed that 
blocking formation of the CD147/MCT complex using an anti-CD147 mAb decreased 
the number of melanoma and colon cancer cells through an accumulation of lactate and a 
decreased pH42. This decreased cell number was exhibited in cancer cells, but not in 
normal fibroblasts42.  
 Our hypothesis was that treating U87MG GBM cells with anti-CD147 mAbs 
would suppress tumor cell growth in a multi-cellular tumor spheroid model. To test this 
hypothesis, U87MG GBM multi-cellular tumor spheroids were grown in 96-well ultra-
low attachment round bottom plates, and treated with anti-CD147 mAbs. During mAb 
treatment, spheroids were measured every 24 hours and compared to controls. The 
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possible mechanism by which the mAbs suppressed cell growth was tested to determine 
if the effects were a result of cell death or cellular proliferation.  
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METHODS AND MATERIALS 
 
 
 
 
Cell Culture 
 
U87MG adherent cells (ATCC) were cultured in Eagle’s Modified Essential 
Medium (EMEM; Corning, Manassas, VA) with 10% Fetal Bovine Serum (FBS; Atlanta 
Biological, Atlanta, GA). The media was supplemented with 1% Penicillin-Streptomycin-
Amphotericin B (PSA; Lonza, Walkersville, MD) to prevent bacterial and fungal 
contamination. Under laminar flow, frozen aliquots of cells were resuspended in 8.5 ml 
of culture media and then transferred to 75cm2 tissue treated flasks. Each flask was 
incubated at 37ºC and 5% CO2 until cells became nearly confluent, where cells were then 
either passaged 1:3, harvested for replating or for spheroid assays.  
Spheroid Antibody Assay 
Once nearly confluent, cells were removed from the flask with trypsin-versene 
(Lonza) and pelleted at 1000 rpm for 5 minutes. Pelleted cells were resuspended in 10 ml 
culture medium, and the live cells were counted using a hemacytometer (Hausser 
Scientific, Horsham, PA) following trypan blue solution staining of the cells (VWR Life 
Science AMRESCO, Radnor, PA). 96-well round bottom ultra low attachment plates 
(Corning) were used for the growth of spheroids. Cells were plated at 500 cells/well in 
100 μl of culture media. Immediately after cell plating, an additional 100 μl of either 
antibody-treated media, or normal culture media was added to each well. Three different 
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anti-CD147 monoclonal antibodies (mAbs) were used throughout the duration of these 
assays – Ab666 (Abcam, Cambridge, MA), MEM-M6/1 (Genetex, Irvine, CA), and P2C2 
(Dr. Robert Belton, University of Illinois). Antibody treatment consisted of two different 
concentrations for each mAb – 2 μg/ml, and 10 μg/ml. Seven wells were used for each 
treatment condition. Spheroid cultures in the 96-well plate were placed into incubation 
and analyzed for growth at 24-hour time points for 7 days. Spheroids were measured 
using an ocular micrometer attached to a Microscoptics IV900 series microscope. A 
Canon EOS Rebel T6 camera attached to the microscope was used to photograph each 
spheroid at 24-hour time points.  
Apoptosis/Necrosis Detection Assay (Abcam) 
24-well tissue treated plates (Corning) were used for cell culture. 12mm poly-d 
lysine coated coverslips (Corning) were placed at the bottom of each well to be used for 
fluorescent microscopy upon assay completion. Cells were plated at 20,000 cells/well in 
500ml of culture media. Immediately after cell plating, an additional 500ml of either 
antibody-treated media, or normal culture media was added to each well. Anti-CD147 
mAb ab666 was used at a concentration of 10 μg/ml for each treatment well. Cells were 
then placed into incubation and grown for 4 days. After day 4, prior to beginning the 
apoptosis/necrosis detection kit, positive control cells were treated with 1 μm 
staurosporine for 3.5 hours to induce cell death. All cells were then washed 2 times with 
500 μl assay buffer, by carefully pipetting the buffer up and down. Next, cells were 
resuspended in 600 μl assay buffer and treated with 6 μl 100X apopxin deep red 
indicator, 3 μl 200X nuclear green, and 3 μl 200X cytocalcein 450 in order to measure 
the presence of apoptotic or necrotic events. Cells were then incubated at room 
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temperature for 45 minutes. After incubation, cells were washed with 500 μl assay buffer 
then resuspended in 500 μl assay buffer. Finally, cells were imaged using cellSens 
software and an Olympus DP72 fluorescent microscope. 
CellQuanti-Blue Proliferation Assay (BioAssay Systems) 
Living cells actively reduce the CellQuanti-Blue solution and convert it into a 
highly fluorescent product. The measured fluorescent activity directly correlates with a 
cells metabolic activity, which provides a relatively easy way to measure cell 
proliferation. For this assay, cells were plated at 5,000 cells/well in 50 μl of culture 
media. Black 96-well clear bottom plates (Corning) were used for cell culture. 
Immediately after cell plating, an additional 50 μl of either antibody-treated media, or 
normal culture media was added to each well. Anti-CD147 mAb ab666 was used at a 
concentration of 10 μg/ml for each treatment well. Cells were then placed into incubation 
and grown for 4 days. After day 4, CellQuanti-Blue reagent was equilibrated to room 
temp then added to each well at a volume of 10 μl. Cells were then incubated at room 
temperature for 2 hours and subsequently analyzed on a Modulus microplate multimode 
reader (Turner Biosystems, Sunnyvale, CA) using a 530 excitation/590 emission filter.  
Statistical Analysis 
Spheroid size was averaged for each culture condition and plotted for daily 
change in growth in Microsoft excel. Data from each antibody concentration was 
analyzed against the control in a paired t-test for each day using GraphPad. Data with a P 
value <0.05 was considered significant. Data with a P value <0.01 was considered highly 
significant. Data with a P value <0.001 was considered extremely significant. For 
apoptosis/necrosis detection, a cell count was done for each stain to determine percent 
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change between control and treated samples. Data from the CellQuanti-Blue proliferation 
assay was calculated as percent change in cell number of treated cells compared with 
controls. Data with a P value <0.05 was considered significant. Data with a P value <0.01 
was considered highly significant. Data with a P value <0.001 was considered the most 
significant.  
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RESULTS 
 
 
 
 
Spheroid Growth 
 Because the literature indicates that CD147 interference/knockdown leads to 
decreased tumor cell survival, it was hypothesized that anti-CD147 mAbs would inhibit 
CD147 function and therefore suppress spheroid growth. Prior to setting up the spheroid 
antibody assay, it was first demonstrated that U87MG cells could form spheroids. 
Initially, two different types of spheroid plates were used. Plates treated with poly-
HEMA and plates treated with agarose were both initially tested. Both substances were 
used because of their relatively low prices and their ability to produce hydrophobic 
surfaces in the culture dish, which favor spheroid growth. Spheroids were able to form in 
both plates, but the bottom of the plates contained so much amorphous material that 
images were distorted, making spheroid measurements impossible. To correct this, ultra-
low attachment plates were purchased from Corning and used for the remainder of the 
study. U87MG cells formed spheroids in these low-attachment plates and allowed for 
clear images.  
Spheroid Antibody Assay 
 Initially, to assure spheroids would grow in the presence of mAbs, 500 U87MG 
cells were plated along with anti-CD147 mAb ab666 at a concentration of 10 μg/ml. 
After incubating overnight, spheroids formed and therefore allowed for the spheroid 
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antibody assay to begin. The spheroid assay was done in three different trials, with seven 
different spheroids grown in each each row for every trial (figure 3). In trial 1, five rows 
were tested. For row A, U87MG cells were plated at 500 cells/well and then treated with 
standard culture media for a final volume of 200 μl. Cells were grown for 7 days and 
measured at 24-hour time points (figures 4-6). For rows B and C, U87MG cells were 
plated at 500 cells/well and then treated with anti-CD147 mAb ab666 at concentrations of 
2 μg/ml and 10 μg/ml, respectively. Spheroids were grown for 7 days and measured at 
24-hour time points (figures 7-9). For rows D and E, U87MG cells were plated at 500 
cells/well and then treated with anti-CD147 mAb P2C2 at concentrations of 2 μg/ml and 
10 μg/ml, respectively. Spheroids were grown for 7 days and measured at 24-hour time 
points (figures 10-12). For trials 2 and 3, a 2nd clone of anti-CD147 mAb MEM-M6/1 
was acquired and used throughout the assays. Trials 2 and 3 now had 7 rows in 
comparison to 5 rows in trial 1. Rows A-E remained the same as trial 1, while 2 new 
culture conditions were added. For rows F and G, U87MG cells were plated at 500 
cells/well and then treated with anti-CD147 mAb MEM-M6/1 at concentrations of 2 
μg/ml and 10 μg/ml, respectively. Spheroids were grown for 7 days and measured at 24-
hour time points (figures 13-15). 
Data for all 3 mabs was averaged and graphed using Microsoft Excel (figures 16-
18). Anti-CD147 mab ab666 significantly suppressed spheroid growth on all days after 
day 1 at a concentration of 10 μg/ml. Growth was suppressed up to 24 percent of the 
control. Anti-CD147 mab P2C2 significantly suppressed spheroid growth on all days 
after day 1 at a concentration of 10 μg/ml. Growth was suppressed up to 11 percent of the 
control. Anti-CD147 mab MEM-M6/1 significantly suppressed spheroid growth on all 
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days after day 1 at a concentration of 10 μg/ml. Growth was suppressed up to 32 percent 
of the control. Taken together, it can be said with confidence that CD147 interference 
through the use of anti-CD147 mAbs significantly suppressed cell growth.  
Apoptosis/Necrosis Assay 
 In order to determine the possible mechanism(s) for anti-CD147 mAb inhibition 
of spheroid growth, a cell death assay was performed. Instead of 96-well plates, 24-well 
plates were used and seeded at a higher density. Well 1 was used as the positive control. 
U87MG cells were plated at 20,000 cells and treated wih standard culture media. After 
growing for 4 days, cells were treated with 1 μm staurosporine for 3.5 hours to induce 
cell death and then imaged on a flurouescence microscope (figures 19-22). Figure 19 
shows live cells, stained with CytoCalcein Violet 450. Figure 20 shows the same culture 
stained for apoptotic cells using the Apopxin Deep Red Indicator. Figure 21 shows 
necrotic cells, stained with Nuclear Green DSC1. Figure 22 shows the overlay image of 
the 3 stains. 3.5 hours of 1 μm staurosporine successfully induced cell death in the 
U87MG cells, demonstrating positive staining for both apoptosis and necrosis. Well 2 
was used as the negative control. U87MG cells were plated at 20,000 cells and treated 
with standard culture media. Cells were grown for 4 days and then imaged on a 
fluroecence microscope (figures 23-26). Figure 23 shows live cells, stained with 
CytoCalcein 450. Figures 24 and 25 were stained for apoptosis and necrosis respectively. 
The results are negative for both stains, meaning that the negative control cells did not 
undergo either mechanism of cell death as a result of the culturing procedures used. 
Figure 26 shows the overlay image for all 3 stains. Well 3 was the anti-CD147 mAb 
treated cells. U87MG cells were plated at 20,000 cells and treated with anti-CD147 mAb 
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ab666 at a concentration of 10 μg/ml. Cells were grown for 4 days and then imaged on a 
fluorescence microscope (figures 27-39). Figure 27 shows live cells, stained with 
CytoCalcein 450. Figures 28 and 29 were stained for apoptosis and necrosis respectively. 
The results were negative for both stains, meaning that the anti-CD147 mAb treated cells 
are not experiencing any mechanism of cell death. Figure 30 is the overlay image of all 3 
stains. All 3 conditions were graphed using Microsoft Excel (figure 31) and expressed as 
a percent change between control and treated samples. The positive control cells showed 
significant amounts of both mechanisms of cell death while the negative control and mAb 
treated cells showed no form of cell death. 
CellQuanti-Blue Proliferation Assay 
 The CellQuanti-Blue proliferation assay followed a similar protocol as previous 
assays. U87MG cells were plated into a 96-well plate at 5,000 cells/well and treated with 
anti-CD147 mAb ab666 at a concentration of 10 μg/ml, or left untreated. After 4 days of 
growth, cells were treated with 10 μl of Cell-Quanti Blue reagent and incubated for 1 
hour. Fluorescent intensity was then measured for each well on a fluorescent microplate 
reader using the 530 excitation/590 emission filter. Graphpad was used to create the 
graph (figure 32) of cell proliferation. Data was expressed as a percent change between 
treated and control samples. Ab666 mAb treatment significantly decreased cell 
proliferation when compared to untreated control cells. A paired t test presented a value 
of 0.005, confirming significance of the data.  
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Figure 1: The Warburg effect. In the presence of oxygen, normal cells produce their 
energy through oxidative phosphorylation. In the absence of oxygen, cells will produce 
energy through anaerobic glycolysis. Cancer cells produce the majority of their energy, 
even in the presence of oxygen, though aerobic glycolysis followed by lactic acid 
fermentation. This is called the Warburg effect. Taken from “Understanding the Warburg 
effect: the metabolic requirements of cell proliferation” by Heiden et al., 2009, Science, 
Vol. 324, pg. 1029-1033. Used with permission. 
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Figure 2: PI3K/Akt/MDM2 pathway. CD147 stimulates the PI3K/Akt/MDM2 
pathway. Activation of this pathway leads to the inhibition of p53, a tumor suppressor 
genes involved in the cell cycle. CD147 inhibition leads to inhibition of the 
PI3K/Akt/MDM2 pathway, and therefore removes the p53 blockade, allowing it to 
perform its proper function. Taken from “CD147 promotes reprogramming of glucose 
metabolism and cell proliferation in HCC cells by inhibiting the p53-dependent signaling 
pathway” by Huang et al., 2014, Journal of Hepatology, Vol. 4, pg. 859-866. Used with 
permission. 
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Figure 3: Spheroid antibody assay experimental design. Row A contains the untreated 
control. Row B contains ab666 at a concentration of 2 ug/ml. Row C contains ab666 at a 
concentration of 10 ug/ml. Row D contains P2C2 at a concentration of 2 ug/ml. Row E 
contains P2C2 at a concentration of 10 ug/ml. Row F contains MEM-M6/1 at a 
concentration of 2 ug/ml. Row G contains MEM-M6/1 at a concentration of 10 ug/ml. 
MEM-M6/1 was only used in trials 2 and 3.  
 
 
Untreated	Control	
Ab666	2	ug/ml	
Ab666	10	ug/ml	
P2C2	2	ug/ml	
P2C2	10	ug/ml	
MEM-M6/1	10	ug/ml	
MEM-M6/1	2	ug/ml	
*	MEM-M6/1	not	used	in	trial	1	
Spheroid	Antibody	Assay	Experimental	Design	
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Figure 4: Untreated U87MG cells – day 0. U87MG cells were plated at 500 cells/well. 
Picture was taken at 4x magnification immediately after cell plating on day 0. 
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Figure 5: Untreated spheroid – day 3. Control well. Cells were plated at 500 cells/well. 
Picture was taken at 4x magnification after 72 hours of growth on day 3. Spheroid is 300 
micrometers. Measurements were taken using an ocular micrometer and converted using 
the 4x magnification scale.  
 
 
 
 
 
 29 
 
Figure 6: Untreated spheroid – day 6. Control well. Cells were plated at 500 cells per 
well. Picture was taken at 4x magnification after 144 hours of growth on day 6. Spheroid 
is 475 micrometers. Measurements were taken using an ocular micrometer and converted 
using the 4x magnification scale. 
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Figure 7: U87MG cells treated with mAb ab666 at 10 μg/ml – day 0. Cells were 
plated at 500 cells per well and treated with anti-CD147 mAb ab666 at a concentration of 
10 μg/ml. Picture was taken at 4x magnification immediately after cell plating on day 0. 
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Figure 8: Spheroid treated with mAb ab666 at 10 μg/ml – day 3. Cells were plated at 
500 cells per well and treated with anti-CD147 mAb ab666 at a concentration of 10 
μg/ml. Picture was taken at 4x magnification after 72 hours of growth on day 3. Spheroid 
is 225 micrometers. Measurements were taken using an ocular micrometer and converted 
using the 4x magnification scale. 
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Figure 9: Spheroid treated with mAb ab666 at 10 μg/ml – day 6. Cells were plated at 
500 cells per well and treated with anti-CD147 mAb ab666 at a concentration of 10 
μg/ml. Picture was taken at 4x magnification after 144 hours of growth on day 6. 
Spheroid is 375 micrometers. Measurements were taken using an ocular micrometer and 
converted using the 4x magnification scale. 
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Figure 10: U87MG cells treated with mAb P2C2 at 10 μg/ml – day 0. Cells were 
plated at 500 cells per well and treated with anti-CD147 mAb P2C2 at a concentration of 
10 μg/ml. Picture was taken at 4x magnification immediately after cell plating on day 0. 
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Figure 11: Spheroid treated with mAb P2C2 at 10 μg/ml – day 3. Cells were plated at 
500 cells per well and treated with anti-CD147 mAb P2C2 at a concentration of 10 
μg/ml. Picture was taken at 4x magnification after 72 hours of growth on day 3. Spheroid 
is 275 micrometers. Measurements were taken using an ocular micrometer and converted 
using the 4x magnification scale. 
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Figure 12: Spheroid treated with mAb P2C2 at 10 μg/ml – day 6. Cells were plated at 
500 cells per well and treated with anti-CD147 mAb P2C2 at a concentration of 10 
μg/ml. Picture was taken at 4x magnification after 144 hours of growth on day 6. 
Spheroid is 425 micrometers. Measurements were taken using an ocular micrometer and 
converted using the 4x magnification scale. 
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Figure 13: U87MG cells treated with mAb MEM-M6/1 at 10 μg/ml – day 0. Cells 
were plated at 500 cells per well and treated with anti-CD147 mAb MEM-M6/1 at a 
concentration of 10 μg/ml. Picture was taken at 4x magnification immediately after cell 
plating on day 0. 
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Figure 14: Spheroid treated with mAb MEM-M6/1 at 10 μg/ml – day 3. Cells were 
plated at 500 cells per well and treated with anti-CD147 mAb MEM-M6/1 at a 
concentration of 10 μg/ml. Picture was taken at 4x magnification after 72 hours of growth 
on day 3. Spheroid is 200 micrometers. Measurements were taken using an ocular 
micrometer and converted using the 4x magnification scale. 
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Figure 15: Spheroid treated with mAb MEM-M6/1 at 10 μg/ml – day 6. Cells were 
plated at 500 cells per well and treated with anti-CD147 mAb MEM-M6/1 at a 
concentration of 10 μg/ml. Picture was taken at 4x magnification after 144 hours of 
growth on day 6. Spheroid is 325 micrometers. Measurements were taken using an ocular 
micrometer and converted using the 4x magnification scale. 
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Figure 16: Average change in spheroid diameter (Ab666). U87MG cells were treated 
with either control culture media or anti-CD147 mAb ab666. 7 spheroids were grown for 
each treatment condition. Antibodies were administered at concentrations of 2 μg/ml and 
10 μg/ml. Cells were grown for a total of 7 days and analyzed at 24-hours time points. 
Ab666 at a concentration of 10 μg/ml suppressed spheroid growth on all days after day 1. 
Growth was suppressed up to 24 percent of the control. A paired t-test indicated that the 
data from all time points was significant when compared to the control.  
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Figure 17: Average change in spheroid diameter (P2C2). U87MG cells were treated 
with either control culture media or anti-CD147 mAb P2C2. 7 spheroids were grown for 
each treatment condition. Antibodies were administered at concentrations of 2 μg/ml and 
10 μg/ml. Cells were grown for a total of 7 days and analyzed at 24-hours time points. 
P2C2 at a concentration of 10 μg/ml suppressed spheroid growth on all days after day 1. 
Growth was suppressed up to 11 percent of the control. A paired t-test indicated that the 
data from all time points was significant when compared to the control.  
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Figure 18: Average change in spheroid diameter (MEM-M6/1). U87MG cells were 
treated with either control culture media or anti-CD147 mAb MEM-M6/1. 7 spheroids 
were grown for each treatment condition. Antibodies were administered at concentrations 
of 2 μg/ml and 10 μg/ml. Cells were grown for a total of 7 days and analyzed at 24-hours 
time points. MEM-M6/1 at a concentration of 10 μg/ml suppressed spheroid growth on 
all days after day 1. Growth was suppressed up to 32 percent of the control. A paired t-
test indicated that the data from all time points was significant when compared to the 
control.  
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Figure 19: Positive control stained positive for live cells. U87MG cells were grown for 
4 days then treated with 1 μm staurosporine in a 37(0), 5% CO2 incubator for 3.5 hours. 
Image shows live cells (blue, stained with CytoCalcein Violet 450). Image was taken 
with an Olympus DP72 fluorescence microscope through the violet channel. Data 
indicates the positive control contained live cells beginning to cluster. 
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Figure 20: Positive control stained positive for apoptosis. U87MG cells were grown 
for 4 days then treated with 1 μm staurosporine in a 37(0), 5% CO2 incubator for 3.5 
hours. Image shows apoptotic cells (red, stained with Apopxin Deep Red Indicator). 
Image was taken with an Olympus DP72 fluorescence microscope through the Cy5 
channel. Data indicates staurosporine treatment induced apoptosis on positive control 
cells. 
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Figure 21: Positive control stained positive for necrosis. U87MG cells were grown for 
4 days then treated with 1 μm staurosporine in a 37(0), 5% CO2 incubator for 3.5 hours. 
Image shows necrotic cells (green, stained with Nuclear Green DCS1). Image was taken 
with an Olympus DP72 fluorescence microscope through the FITC channel. Data 
indicates staurosporine treatment induced necrosis on positive control cells. 
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Figure 22: Positive control overlay image. U87MG cells were grown for 4 days then 
treated with 1 μm staurosporine in a 37(0), 5% CO2 incubator for 3.5 hours. Image shows 
cells that are alive (blue, stained with CytoCalcein Violet 450), apoptotic cells (red, 
stained with Apopxin Deep Red Indicator), and necrotic cells (green, stained with 
Nuclear Green DCS1). Image shows cells beginning to go through both apoptosis and 
necrosis due to staurosporine treatment. Overlay was produced from the same population 
of cells. Image was taken with an Olympus DP72 fluorescence microscope through the 
violet, Cy5, and FITC channel respectively.  
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Figure 23: Negative control stained positive for live cells. Untreated U87MG cells 
were grown in a 37(0), 5% CO2 incubator for 4 days. Image shows live cells (blue, 
stained with CytoCalcein Violet 450). Image was taken with an Olympus DP72 
fluorescence microscope through the violet channel. Data indicates that the negative 
control contained living cells. 
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Figure 24: Negative control stained negative for apoptosis. Untreated U87MG cells 
were grown in a 37(0), 5% CO2 incubator for 4 days. Cells were stained for apoptosis 
(red, Apopxin Deep Red Indicator). No apoptosis was detected. Image was taken with an 
Olympus DP72 fluorescence microscope through the Cy5 channel.  
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Figure 25: Negative control stained negative for necrosis. Untreated U87MG cells 
were grown in a 37(0), 5% CO2 incubator for 4 days. Cells were stained for necrosis 
(green, Nuclear Green DCS1). No necrosis was detected. Image was taken with an 
Olympus DP72 fluorescence microscope through the FITC channel.  
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Figure 26: Negative control overlay image. Untreated U87MG cells were grown in a 
37(0), 5% CO2 incubator for 4 days. Cells were stained for live cells (blue, stained with 
CytoCalcein Violet 450), apoptotic cells (red, stained with Apopxin Deep Red Indicator), 
and necrotic cells (green, stained with Nuclear Green DCS1). Image shows only live 
cells, indicating that the negative control cells are going through neither apoptosis nor 
necrosis. Overlay was produced from the same population of cells. Image was taken with 
an Olympus DP72 fluorescence microscope through the violet, Cy5, and FITC channel 
respectively.  
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Figure 27: Anti-CD147 mAb treated cells stained positive for live cells. U87MG cells 
were treated with ab666 mAb (10 μg/ml) in a 37(0), 5% CO2 incubator for 4 days. Image 
shows live cells (blue, stained with CytoCalcein Violet 450). Image was taken with an 
Olympus DP72 fluorescence microscope through the violet channel.  
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Figure 28: Anti-CD147 mAb treated cells stained negative for apoptosis. U87MG 
cells were treated with ab666 mAb (10 μg/ml) in a 37(0), 5% CO2 incubator for 4 days. 
Cells were stained for apoptosis (red, Apopxin Deep Red Indicator). No apoptosis was 
detected. Image was taken with an Olympus DP72 fluorescence microscope through the 
Cy5 channel.  
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Figure 29: Anti-CD147 mAb treated cells stained negative for necrosis. U87MG cells 
were treated with ab666 mAb (10 μg/ml) in a 37(0), 5% CO2 incubator for 4 days. Cells 
were stained for necrosis (green, Nuclear Green DCS1). No necrosis was detected. Image 
was taken with an Olympus DP72 fluorescence microscope through the FITC channel.  
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Figure 30: Anti-CD147 mAb treated cells overlay image. U87MG cells were treated 
with ab666 mAb (10 μg/ml) in a 37(0), 5% CO2 incubator for 4 days. Cells were stained 
for live cells (blue, stained with CytoCalcein Violet 450), apoptotic cells (red, stained 
with Apopxin Deep Red Indicator), and necrotic cells (green, stained with Nuclear Green 
DCS1). Image shows only live cells, indicating that the antibody treatment caused neither 
apoptosis nor necrosis. Overlay was produced from the same population of cells. Image 
was taken with an Olympus DP72 fluorescence microscope through the violet, Cy5, and 
FITC channel respectively.  
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Figure 31: Anti-CD147 mAb treatment does not induce cell death. Analysis of 
apoptosis and necrosis on U87MG cells after 4 days in the presence of ab666 mAb (10 
μg/ml), staurosporine (1 μm), or no treatment. No cell death was observed in the negative 
control nor the mAb treated cells. Data was expressed as percent change between control 
and treated samples. Apoptosis and necrosis was only detected in the positive control 
cells treated with 1 μm staurosporine.  
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Figure 32. Anti-CD147 mAb treatment caused decreased cell proliferation. Analysis 
of cell proliferation in U87MG cells after 4 days of ab666 mAb treatment (10 μg/ml), or 
no treatment. Cell proliferation significantly decreased in the mAb treated cells. Data was 
expressed as percent change between control and treated samples. 
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DISCUSSION 
 
 
 
 While it has been shown that CD147 interference/knockdown suppresses cell 
growth in adherent melanoma and colon cancer cells42, this would be a novel finding in 
GBM multicellular tumor spheroids. In the present work, we have shown that anti-CD147 
mAbs (ab666, MEM-M6/1, & P2C2) significantly suppress U87MG spheroid growth. 
Previous studies have demonstrated that CD147 forms a complex with monocarboxlate 
transporters on the cell surface, and it seems this interaction is crucial for tumor cell 
survival42. Directly downstream of the CD147/MCT complex lies the PI3K/Akt/MDM2 
pathway – an important system that controls the tumor suppressor gene p5351. P53 
activity is increased in response to cellular stress such as DNA damage and oncogene 
activation52. The primary regulator of p53 is MDM2, which functions to inhibit p53 
transcriptional activation52. One specific study showed that phosphorylation of Akt and 
MDM2 was significantly decreased when CD147 was either knocked down or knocked 
out51. Additionally, p53 levels increased when CD147 was being inhibited51. This 
highlights a direct correlation between CD147 and the PI3K/Akt/MDM2 pathway. The 
study also highlighted an inverse correlation between lactic acidosis and PI3K/Akt 
activity, showing that Akt activity was reduced by a MCT1 inhibitor51. Additionally, Akt 
activity was significantly increased in MCT1 overexpressing cells. This highlights the 
importance of the CD147/MCT complex in the function of the PI3K/Akt/MDM2 
pathway. Specific growth factors are responsible for activation of the PI3K/Akt/MDM2 
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pathway, and one molecule that lays directly upstream is EGFR, a receptor tyrosine 
kinase. To become activated, RTKs generally require ligand binding that eventually leads 
to phosphorylation of the receptor. However, in cancer, RTKs can become 
phosphorylated in the absence of a ligand54. Overexpression or mutations of these 
receptors can lead to clustering, causing them to homodimerize and become 
phosphorylated. This autophosphorylation leads to constant activation of the pathway, 
which can eventually lead to cancer. As mentioned previously, all of this data suggests 
that the CD147/MCT complex along with EGFR activity play a role in activating the 
PI3K/Akt/MDM2 pathway. We believe that interfering with CD147 function may 
subsequently inhibit the PI3K/Akt/MDM2 pathway, leading to increased p53 expression 
and its tumor suppressing properties. 
While Baba et al. reported similar findings to ours in their 2008 paper; there are 
key differences with our current work. Baba et al. reported that inhibiting expression of 
the CD147/MCT complex using mAb ab666 decreased the number of melanoma and 
colon cancer cells, but not normal fibroblasts42. While searching for the mechanism to 
explain this finding, an apoptosis assay was done which resulted in negative data. It was 
then assumed that since the hallmarks of apoptosis were not seen, the reason for 
decreased cell numbers was necrotic cell death. This is a major assumption because other 
factors could be causing this, such as an interruption of cellular metabolism leading to 
decreased proliferation. We investigated this possibility by using multicellular spheroids. 
Once cell culture conditions were optimized, multicellular tumor spheroids were grown 
using U87MG cells and treated with the same mAb used by Baba et al., along with two 
other anti-CD147 mAbs. As hypothesized, these anti-CD147 mAbs significantly 
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suppressed spheroid growth during the 7-day treatment. An interesting finding within 
these results is that two of the mAbs (ab666 & MEM-M6-1) had more significant effects 
on spheroid growth than the other (P2C2). In fact, the two mAbs that showed higher 
significance are the same mAb clone produced by different manufacturers. According to 
both manufacturers, this antibody clone recognizes and binds to an epitope in the N-
terminal Ig domain (D1). This could be an important factor for the difference seen 
between the effects of the different mAbs. The site at which an antibody binds, whether 
extracellularly or intracellularly, could play a large role in mab effect. 
 In order to determine how these mAbs suppressed spheroid growth, a cell death 
assay for both apoptosis and necrosis was used. Using the same culture conditions, 
U87MG cells were grown in the presence of ab666 for four days. To test for these 
mechanisms of cell death, positive control cells, negative control cells, and mAb treated 
cells were stained with three different stains after the growth period was complete. 
Positive control cells are used to represent the response being tested, whereas negative 
control cells represent normal cells with no response. A live cell stain, an apoptosis stain, 
and a necrosis stain were all used in combination to test for cell death in all three culture 
conditions. The live stain (CytoCalcein Violet 450) works by entering the cytoplasm of 
live cells, where specific esterases cleave an ester group from the stain, which yields the 
fluorescent dye. Dead cells that have compromised cell membranes are not able to 
complete this process. The apoptotic stain (Apopxin Deep Red) works by binding directly 
to phosphatidylserine, which moves to the outside of the cell during apoptosis allowing 
for easy detection which is observed as red fluorescent light. Phosphatidylserine on the 
cell surface is a universal indicator of the early signs of apoptosis, and can be detected 
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before cell morphology changes drastically. The necrotic stain (Nuclear Green DCS1) is 
a membrane impermeable dye that enters the nucleus of cells that have lost their 
membrane integrity due to cellular damage and fluoresces as green light. As expected, the 
positive control cells treated with staurosporine, which induces cell death, stained 
positive for both apoptosis and necrosis. Again, as expected, the untreated negative 
control cells were negative for both apoptosis and necrosis staining. Like Baba et al., our 
mAb treated cells were negative for apoptosis staining. Our results differed, though, 
when it came to necrotic cell death. The mAb treated cells were also negative for necrosis 
staining, which raised the question of how these cells could be experiencing a decrease in 
cell growth. 
A literature review of tumor cell proliferation was performed to find a possible 
clue to explain our results. We learned that the CD147/MCT complex lies directly 
upstream of the PI3K/Akt/MDM2 pathway51. We also learned that EGFR lies directly 
upstream of the pathway and acts as a functional regulator for PI3K/Akt/MDM2 
activation53. Finally, it was learned that CD147 forms a complex with EGFR inside lipid 
rafts of the plasma membrane, which could have serious implications in our study56. 
CD147 and EGFR are both overexpressed in GBM, which leads to increased tumor cell 
survival by promoting cancerous properties. Since EGFR acts as a regulator for the 
PI3K/Akt/MDM2 pathway, its activation leads to activation of the pathway. 
Overexpression of EGFR may cause receptor clustering and can eventually lead to 
homodimerization and autophosphorylation of the receptor. This would activate the 
pathway in the absence of a ligand, ultimately promoting cancer. The PI3K/Akt/MDM2 
pathway is critical for cellular functions such as proliferation, glucose metabolism, and 
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angiogenesis.  
When functioning properly, p53 can inhibit the downstream effects of the 
PI3K/Akt/MDM2 signaling pathway in tumor cells. Using the CellQuanti-Blue 
proliferation assay, we analyzed the proliferation of mAb treated cells versus control 
cells. After growing cells in both conditions for 4 days, cells were stained with 
CellQuanti-Blue reagent and incubated for an hour. Following incubation, cells were 
analyzed for total fluorescence, which represents proliferation. Overall, the mAb treated 
cells had a decreased proliferation rate of nearly 40% when compared with the control. 
Rather than cell death, these GBM cells treated with anti-CD147 mAbs appear to 
experience a significant decrease in cell proliferation. Reviewing the literature gives a 
molecular basis for these results. Interference of the CD147/MCT/EGFR complexes has 
potential to cause serious problems for tumor cell survival. We believe that anti-CD147 
mAb binding is causing internalization of these complexes, inhibiting their function and 
leading to inhibition of the PI3K/Akt/MDM2 pathway. Since these complexes carry out 
their functions on the cell surface, internalization into the cell would prevent them from 
being able to function properly. Overall, the inhibition of this pathway would remove the 
inhibition of tumor suppressor p53 and allow it to carry out its proper function – 
suppressing tumor cells. 
 To further analyze the effects of our different mAbs, epitope mapping of each 
antibody should be done to confirm exactly where each mAb is binding to its target 
protein. Locating the exact binding site of an antibody provides crucial information when 
developing a new therapeutic drug. Further analysis of the PI3K/Akt/MDM2 pathway 
should also be completed to confirm the hypothesis of its downstream role in tumor cell 
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proliferation. Following mAb treatment, cellular levels of EGFR, Akt and p53 could be 
measured and compared to a control. Other techniques besides mAb treatment could also 
be used to inhibit CD147 function, such as a true knockdown or knockout to analyze the 
effects it may have on this pathway. 
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CONCLUSION 
 
 
 
 In conclusion, we have demonstrated that anti-CD147 monoclonal antibodies 
suppress the growth of U87MG multicellular tumor spheroids. Furthermore, we have 
shown that when treated with these mAbs, U87MG cells are not undergoing apoptosis or 
necrosis. We have also shown that cellular proliferation is significantly decreased post 
antibody treatment, showing a decreased proliferation rate of nearly 40 percent when 
compared with control cells. It is likely that these findings are a result of the 
PI3K/Akt/MDM2 pathway being subsequently inhibited by CD147 interference, although 
further analysis will be needed to confirm this hypothesis. For future GBM treatment, we 
have came to two important conclusions; monoclonal antibodies can be used to target the 
specific CD147 protein, and CD147 is a worthwhile therapeutic target for GBM. 
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APPENDIX A 
 
 
 
License to use Figure 1 from “Understanding the Warburg effect: the metabolic 
requirements of cell proliferation” by Heiden et al. received from The American 
Association for the Advancement of Science.
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APPENDIX B 
 
 
 
License to use Figure 2 from “CD147 promotes reprogramming of glucose metabolism 
and cell proliferation in HCC cells by inhibiting the p53-dependent signaling pathway” 
by Huang et al. received from Elsevier Publishing.
 
